Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, with core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules. Its lead product, PALSONIFY (paltusotine), is the first once-daily oral FDA-approved treatment for adults with acromegaly who had an inadequate response to surgery. The company also has a pipeline including atumelnant for congenital adrenal hyperplasia (CAH) and trades publicly on Nasdaq as CRNX.